USANA Health Sciences (NYSE:USNA) Issues Earnings Results

USANA Health Sciences (NYSE:USNA) announced its quarterly earnings data on Tuesday. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.17, FiscalAI reports. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%.The company had revenue of $250.22 million for the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences updated its FY 2026 guidance to 1.950-2.290 EPS.

USANA Health Sciences Stock Up 3.4%

Shares of USANA Health Sciences stock traded up $0.63 during trading on Tuesday, hitting $19.19. 97,344 shares of the company were exchanged, compared to its average volume of 124,924. USANA Health Sciences has a fifty-two week low of $16.60 and a fifty-two week high of $38.32. The stock has a market capitalization of $354.13 million, a price-to-earnings ratio of 34.89, a P/E/G ratio of 0.83 and a beta of 0.77. The firm has a 50 day moving average price of $18.58 and a 200 day moving average price of $19.73.

Insider Activity

In related news, insider Joshua Foukas sold 4,461 shares of USANA Health Sciences stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $21.34, for a total transaction of $95,197.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.82% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. raised its holdings in USANA Health Sciences by 4.6% in the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock valued at $244,000 after acquiring an additional 542 shares during the last quarter. Quantbot Technologies LP increased its holdings in shares of USANA Health Sciences by 19.5% during the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after buying an additional 646 shares during the last quarter. Intech Investment Management LLC boosted its position in USANA Health Sciences by 13.5% during the 3rd quarter. Intech Investment Management LLC now owns 7,722 shares of the company’s stock worth $213,000 after purchasing an additional 918 shares during the period. National Bank of Canada FI boosted its position in USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after purchasing an additional 1,201 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in USANA Health Sciences by 52.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after purchasing an additional 1,327 shares during the period. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on USNA. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a report on Friday, March 27th. Zacks Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Finally, Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.